This submission is an educational resource (48-slide presentation) suitable for higher education, specifically targeting courses in Pharmacology, Clinical Pharmacy, Medical Genetics, and Biomedicine. Authored by Dr. Brian Pollo, the resource details the foundational principles of pharmacogenomics and the clinical impact of genetic variation on individual drug response. The presentation serves as a self-contained learning module covering: - Pharmacokinetics: In-depth analysis of Phase I and Phase II drug metabolism via enzymes like CYP3A, CYP2D6, CYP2C19, DPYD, and TPMT. Clinical examples include dosing for tacrolimus, omeprazole, and management of 5-fluorouracil (5-FU) toxicity. - Pharmacodynamics: Focus on how genetic variation affects drug targets, leading to variable patient outcomes and adverse events such as Toxic Epidermal Necrolysis (TEN), Stevens-Johnson Syndrome (SJS), and statin-associated myopathy. - Personalized Medicine: Integration of genetic testing concepts and clinical pharmacogenetics guidelines (e.g., CPIC) to guide evidence-based, tailored drug therapy. Target Audience: Advanced Undergraduate, Graduate, and Professional Students (Medical, Pharmacy, Nursing).This extensive 48-slide presentation, created by Dr. Brian Pollo, is a valuable educational resource for students and practitioners in the fields of Pharmacology, Clinical Pharmacy, Medical Genetics, and Biomedicine. It is structured to provide a comprehensive understanding of pharmacogenomics, focusing on the fundamental principles that govern how genetic variation mediates individual drug response.